Warfarin dosing: the role of genes

Warfarin dosing: the genes VKORC1, CYP2C9, CYP4F2 are determinants in the dosing of warfarin. Role in clinical practice of pharmacogenomics: genetic testing to guide warfarin therapy.

FDA recommendations on clopidogrel (Plavix) because of decreased response and PPI interactions

Pharmamotion has now a new page containing updates onĀ  clopidogrel PPI interactions. The FDA issued today an early communication about an ongoing safety review of the antiplatelet agent clopidogrel bisulfate (Plavix). The backgroung to this is the recent evidence of: A decreased response to clopidogrel in some patients. Since clopidogrel is a prodrug, genetic polymorphisms […]

Genetic variants of cytochrome P-450 linked to decreased response to clopidogrel (Plavix,Iscover and others)

From Physician’s First Watch: Genetic Variants Linked to Decreased Response to Clopidogrel, Increased Cardiovascular Risk Polymorphisms in the gene encoding the cytochrome P-450 2C19 enzyme (CYP2C19) not only confer reduced response to clopidogrel, but also are associated with increased risk for cardiovascular events, according to three studies published online by the New England Journal of […]

Are you a visual learner interested in learning psychopharmacology? Click here to get our videos